A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201

被引：38
|
作者：
Loehrer, P. J., Sr.
Powell, M. E.
Cardenes, H. R.
Wagner, L.
Brell, J. M.
Ramanathan, R. K.
Crane, C. H.
Alberts, S. R.
Benson, A. B., III
机构：
[1] Indiana Univ, Eastern Cooperat Oncol Grp, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Northwestern Univ, Chicago, IL 60611 USA
[4] Case Western Reserve Univ, Cleveland, OH 44106 USA
[5] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA
[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[7] Mayo Clin, Rochester, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.4506
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4506
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase II trial of weekly gemcitabine and bevacizumab in combination with abdominal radiation therapy in patients with localized pancreatic cancer
    Small, W.
    Mulcahy, M.
    Rademaker, A.
    Benson, A.
    Bentrem, D.
    Talamonti, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : S6 - S6
  • [22] Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study)
    Ozaka, Masato
    Matsumura, Yuji
    Ishii, Hiroshi
    Omuro, Yasushi
    Itoi, Takao
    Mouri, Hisatsugu
    Hanada, Keiji
    Kimura, Yasutoshi
    Maetani, Iruru
    Okabe, Yoshinobu
    Tani, Masaji
    Ikeda, Takaaki
    Hijioka, Susumu
    Watanabe, Ryouhei
    Ohoka, Shinya
    Hirose, Yuki
    Suyama, Masafumi
    Egawa, Naoto
    Sofuni, Atsushi
    Ikari, Takaaki
    Nakajima, Toshifusa
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (05) : 1197 - 1204
  • [23] Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study)
    Masato Ozaka
    Yuji Matsumura
    Hiroshi Ishii
    Yasushi Omuro
    Takao Itoi
    Hisatsugu Mouri
    Keiji Hanada
    Yasutoshi Kimura
    Iruru Maetani
    Yoshinobu Okabe
    Masaji Tani
    Takaaki Ikeda
    Susumu Hijioka
    Ryouhei Watanabe
    Shinya Ohoka
    Yuki Hirose
    Masafumi Suyama
    Naoto Egawa
    Atsushi Sofuni
    Takaaki Ikari
    Toshifusa Nakajima
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 1197 - 1204
  • [24] A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.
    Scott, Aaron James
    O'Neil, Bert H.
    Gomes, Christina
    Baranda, Joaquina Celebre
    Cohen, Steven J.
    Tejani, Mohamedtaki Abdulaziz
    Maguire, Robert T.
    Wilhelm, Francois
    Maniar, Manoj
    Cohen, Deirdre Jill
    Ma, Wen Wee
    Aisner, Dara
    Cho, Jonathan K.
    Olowokure, Olugbenga Olanrele
    Coveler, Andrew L.
    Menter, Alex R.
    Rubin, Peter
    Cusnir, Mike
    Messersmith, Wells A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [25] A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer
    El-Khoueiry, A. B.
    Ramanathan, R. K.
    Yang, D. Y.
    Zhang, W.
    Shibata, S.
    Wright, J. J.
    Gandara, D.
    Lenz, H. J.
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (03) : 1175 - 1183
  • [26] A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer
    A. B. El-Khoueiry
    R. K. Ramanathan
    D. Y. Yang
    W. Zhang
    S. Shibata
    J. J. Wright
    D. Gandara
    H. J. Lenz
    Investigational New Drugs, 2012, 30 : 1175 - 1183
  • [27] A Randomized Phase II Trial of Adjuvant Chemotherapy With Uracil/Tegafur and Gemcitabine Versus Gemcitabine Alone in Patients With Resected Pancreatic Cancer
    Yoshitomi, Hideyuki
    Togawa, Akira
    Kimura, Fumio
    Ito, Hiroshi
    Shimizu, Hiroaki
    Yoshidome, Hiroyuki
    Otsuka, Masayuki
    Kato, Atsushi
    Nozawa, Satoshi
    Furukawa, Katsunori
    Miyazaki, Masaru
    CANCER, 2008, 113 (09) : 2448 - 2456
  • [28] Phase I study of a chloroquine-gemcitabine combination in patients with metastatic or unresectable pancreatic cancer
    Samaras, Panagiotis
    Tusup, Marina
    Thi Dan Linh Nguyen-Kim
    Seifert, Burkhardt
    Bachmann, Helga
    von Moos, Roger
    Knuth, Alexander
    Pascolo, Steve
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (05) : 1005 - 1012
  • [29] Retrospective Study of Gemcitabine plus S-1 versus Gemcitabine Alone in Cases with Unresectable Advanced Pancreatic Cancer
    Suzuki, Shuji
    Ozaki, Yuhi
    Saida, Shin
    Kaji, Satoshi
    Koike, Nobusada
    Harada, Nobuhiko
    Hayashi, Tsuneo
    Suzuki, Mamoru
    HEPATO-GASTROENTEROLOGY, 2013, 60 (124) : 916 - 920
  • [30] Phase I study of weekly gemcitabine as a radiation sensitizer for unresectable pancreatic cancer
    Poggi, MM
    Kroog, GS
    Russo, A
    Muir, C
    Cook, J
    Smith, J
    Mitchell, JB
    Herscher, LL
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 54 (03): : 670 - 676
12345